← back to search

Minoli A. Perera

Northwestern Medicine · US
Area of research
Pharmacology · Genetics
Research interest
Research interests include Pharmacogenetics and Drug Metabolism, Genetic Associations and Epidemiology, Hormonal Regulation and Hypertension, and Antiplatelet Therapy and Cardiovascular Diseases.
h-index
35
citations
5,133
works
124
NIH funding
primary concept
email

Recent publications

Discovery of ancestry-specific variants associated with clopidogrel response among Caribbean Hispanics
npj Genomic Medicine 2025cited by 3position: middledoi
Meta-analysis of genome-wide association studies of stable warfarin dose in patients of African ancestry
Blood Advances 2024cited by 8position: middledoi
Discovery of Ancestry-specific Variants Associated with Clopidogrel Response among Caribbean Hispanics
medRxiv 2023cited by 1position: middledoi
Warfarin Dosing in Patients With <i>CYP2C9*5</i> Variant Alleles
Clinical Pharmacology & Therapeutics 2022cited by 14position: middledoi
Implementation of pharmacogenomics into inpatient general medicine
Pharmacogenetics and Genomics 2022cited by 13position: middledoi
Why African Americans Say “No”: A Study of Pharmacogenomic Research Participation
Ethnicity & Disease 2020cited by 15position: middledoi
Genetic Factors Influencing Warfarin Dose in Black‐African Patients: A Systematic Review and Meta‐Analysis
Clinical Pharmacology & Therapeutics 2019cited by 64position: middledoi
Differences in Warfarin Pharmacodynamics and Predictors of Response Among Three Racial Populations
Clinical Pharmacokinetics 2019cited by 20position: middledoi
Hepatocyte gene expression and DNA methylation as ancestry-dependent mechanisms in African Americans
npj Genomic Medicine 2019cited by 17position: lastdoi
The <scp>ACCO</scp>u<scp>NT</scp> Consortium: A Model for the Discovery, Translation, and Implementation of Precision Medicine in African Americans
Clinical and Translational Science 2018cited by 43position: lastdoi
Association of Genetic Variants With Warfarin-Associated Bleeding Among Patients of African Descent
JAMA 2018cited by 32position: lastdoi
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics‐Guided Warfarin Dosing: 2017 Update
Clinical Pharmacology & Therapeutics 2017cited by 688position: middledoi
Novel genetic predictors of venous thromboembolism risk in African Americans
Blood 2016cited by 60position: lastdoi
Population differences in S-warfarin pharmacokinetics among African Americans, Asians and whites: their influence on pharmacogenetic dosing algorithms
The Pharmacogenomics Journal 2016cited by 22position: middledoi
Factors Influencing Pharmacokinetics of Warfarin in African–Americans: Implications for Pharmacogenetic Dosing Algorithms
Pharmacogenomics 2015cited by 19position: middledoi
Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans
Blood 2014cited by 58position: lastdoi
Warfarin Pharmacogenetics: An Illustration of the Importance of Studies in Minority Populations
Clinical Pharmacology & Therapeutics 2014cited by 43position: firstdoi
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study
The Lancet 2013cited by 275position: firstdoi
Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans
The Pharmacogenomics Journal 2013cited by 61position: lastdoi
Pathway analysis of genome-wide data improves warfarin dose prediction
BMC Genomics 2013cited by 35position: middledoi
VKORC1 Asp36Tyr geographic distribution and its impact on warfarin dose requirements in Egyptians
Thrombosis and Haemostasis 2013cited by 32position: middledoi
CYP2C9 promoter region single-nucleotide polymorphisms linked to the R150H polymorphism are functional suggesting their role in CYP2C9*8-mediated effects
Pharmacogenetics and Genomics 2013cited by 21position: middledoi
The Future of Warfarin Pharmacogenetics in under-represented Minority Groups
Future Cardiology 2012cited by 65position: lastdoi
Effect of <i>NQO1</i> and <i>CYP4F2</i> Genotypes on Warfarin Dose Requirements in Hispanic–Americans and African–Americans
Pharmacogenomics 2012cited by 61position: middledoi
The limits of genome-wide methods for pharmacogenomic testing
Pharmacogenetics and Genomics 2012cited by 35position: lastdoi

Grants

No grants ingested yet.

Frequent collaborators

Larisa H. Cavallari · American Association of Colleges of Pharmacy16 papers (2012–2022)Shitalben Patel · University of Illinois Chicago7 papers (2012–2022)Edith A. Nutescu · University of Illinois Chicago6 papers (2015–2022)Julie A. Johnson · University of Chicago5 papers (2013–2022)Eric R. Gamazon · New York University5 papers (2012–2019)Matthew Tuck · George Washington University4 papers (2013–2020)Stuart A. Scott · Stanford Health Care4 papers (2017–2025) · 4 papers (2013–2019)Teri E. Klein · Stanford University4 papers (2013–2018) · 3 papers (2019–2025) · 3 papers (2015–2019)Wenndy Hernandez · University of Illinois Chicago3 papers (2015–2018)Nita A. Limdi · University of Alabama at Birmingham3 papers (2013–2022)Rick A. Kittles · University of Illinois Chicago3 papers (2012–2016)Arthur F. Harralson · George Washington University3 papers (2013–2018)Cristina Alarcón · Hospital Marina Baixa3 papers (2018–2025)Paula N. Friedman · Northwestern University3 papers (2018–2022) · 3 papers (2019–2025)Guang Yang · University of Florida2 papers (2023–2025)Dagmar F. Hernández-Suárez · Florida International University2 papers (2023–2025)